Wegovy Insurance Denied? How to Appeal Your Weight Loss Medication Denial and Get Covered

Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 specifically for chronic weight management — the first GLP-1 receptor agonist approved at this dose for obesity. The STEP clinical trial program demonstrated 15 to 17 percent average body weight reduction over 68 weeks, and the 2023 SELECT trial (Lincoff et al., NEJM 2023) showed semaglutide reduced major adverse cardiovascular events by 20 percent in patients with obesity and established cardiovascular disease. Despite this evidence base, insurance denials for Wegovy remain epidemic. FDA approval does not equal insurance coverage, and the gap between the two requires a targeted appeal strategy.

Why Insurers Deny Wegovy Claims

Blanket anti-obesity medication exclusion. The most common denial basis. Many employer-sponsored plans and commercial plans explicitly exclude weight-loss medications from the formulary or from coverage altogether. ERISA-governed self-funded employer plans may implement this exclusion without regard to state insurance mandates.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization criteria not met. Nearly every insurer that covers Wegovy requires prior authorization. Common prior auth criteria include documented BMI of 30 or greater (or 27 with a qualifying comorbidity), evidence of participation in a structured weight management program, and documentation that alternative treatments were tried and failed. Denials often result from incomplete submissions rather than genuine clinical ineligibility.

Step therapy not completed. Many insurers require documented failure of one or more less expensive weight management interventions — supervised diet programs, behavioral therapy, or older anti-obesity medications such as orlistat or phentermine-topiramate — before approving Wegovy. The step therapy requirement must be met or formally overridden.

BMI below insurer's threshold. Some insurers apply BMI thresholds more restrictive than the FDA indication. The FDA approved Wegovy for BMI 30 or greater, or 27 or greater with at least one weight-related comorbidity. If your insurer requires BMI 35 or has other heightened criteria, the FDA approval directly contradicts that threshold.

Plan exclusion of "lifestyle medications." Some insurers characterize weight management medications as lifestyle drugs, outside the scope of covered medical treatment, despite the American Medical Association's 2013 recognition of obesity as a chronic disease (ICD-10: E66) requiring medical management.

Off-label use characterization. If semaglutide was prescribed at the Ozempic dose (1 mg) for weight management rather than the Wegovy formulation (2.4 mg), the insurer may deny as off-label use. Wegovy at 2.4 mg is the on-label formulation for weight management — this distinction matters in the appeal.

How to Appeal a Wegovy Insurance Denial

Step 1: Identify the Specific Denial Basis and Request the Clinical Criteria

Request the full clinical policy bulletin the insurer used to evaluate your prior authorization or claim. Under federal and state law, you are entitled to this information. Compare the insurer's criteria against the FDA-approved indication for Wegovy and against the American Obesity Association's clinical guidelines. Where the insurer's criteria are more restrictive than the FDA indication, document that discrepancy as the central argument in your appeal.

Step 2: Document BMI and Weight-Related Comorbidities Comprehensively

Your medical records must include BMI measurements from clinical settings at multiple visits, showing a consistent pattern of obesity or overweight with qualifying comorbidities. Include actual height and weight measurements — not just the calculated BMI. Document every weight-related comorbidity with supporting objective data: HbA1c levels for diabetes, blood pressure readings for hypertension, sleep study results for obstructive sleep apnea, lipid panels for dyslipidemia, and echocardiography or cardiovascular risk score for cardiovascular disease.

Step 3: Invoke the SELECT Trial for Cardiovascular Disease Comorbidity

If you have established cardiovascular disease — prior myocardial infarction, stroke, or peripheral arterial disease — cite the SELECT trial directly in your appeal: Lincoff et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," NEJM 2023, showing 20 percent reduction in major adverse cardiovascular events (HR 0.80, 95% CI 0.72 to 0.90). This reframes Wegovy not as a weight loss drug but as a cardiovascular outcomes medication for high-risk patients — an entirely different coverage argument that bypasses anti-obesity medication exclusions.

Step 4: Override Step Therapy With State Law or Clinical Exception

If the insurer requires step therapy, check whether your state has enacted a step therapy override law — more than 30 states have. Step therapy override applies when: the required step medication was previously tried and failed, the required medication is contraindicated, or your physician certifies that delay of the prescribed treatment would cause adverse health outcomes. Document every prior weight management intervention — dates, duration, program, outcomes, and reasons for discontinuation or failure.

Step 5: Request a Formulary Exception for Non-Covered Plans

If Wegovy is not on your plan's formulary, file a formulary exception request. Your prescribing physician must document that Wegovy is medically necessary for your specific clinical profile and that formulary alternatives are inadequate or contraindicated. For ACA marketplace plans, the insurer must respond to formulary exception requests within 72 hours for standard requests and 24 hours for expedited urgent requests under 45 CFR 147.136(b).

Step 6: File for Independent External Independent Review: Complete Guide" class="auto-link">External Review After Internal Appeal Denial

Under ACA (45 CFR 147.136(d)), if your internal appeal is denied, you have the right to free independent external review. External reviewers apply objective clinical standards and have access to the same published evidence your physician cites. The combination of FDA approval, STEP trial data, SELECT trial data, and AMA disease recognition creates a strong external review record. File simultaneously with your state Department of Insurance.

What to Include in Your Wegovy Insurance Appeal

• Clinical-setting BMI measurements from multiple visits with supporting comorbidity documentation and ICD-10 codes
• SELECT trial citation if cardiovascular disease is present (NEJM 2023, 20% MACE reduction)
• STEP trial data summary from your physician's letter establishing Wegovy's 15 to 17 percent weight reduction evidence base
• Step therapy documentation: dates, programs, medications tried, outcomes, and reasons for failure
• State step therapy override law citation if your plan is state-regulated
• Formulary exception request with physician attestation if Wegovy is non-formulary

Fight Back With ClaimBack

Wegovy denials based on formulary exclusion, step therapy, or prior authorization criteria are frequently reversed when the appeal reframes semaglutide as a cardiovascular outcomes medication for high-risk patients and documents comorbidities comprehensively. ClaimBack generates a professional appeal letter in 3 minutes, citing the SELECT trial, STEP trial data, AMA disease recognition, and the applicable ERISA and ACA regulatory framework. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal